A Study of BGB-A445 in Combination With Other Investigational Agents in Participants With Non-Small Cell Lung Cancer

• Status: Recruiting
• Trial end date: 2026-05-01
• Target enrollment: 0
• Participant gender: All

Summary

The main objective of this study is to evaluate the anti-tumor activity of BGB-A445 plus investigational agents in participants with non-small cell lung cancer (NSCLC)

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: BeiGene
• Treatments: Docetaxel; Ramucirumab

Criteria

Inclusion Criteria:

• Advanced or metastatic NSCLC (nonsquamous or squamous) that is histologically or cytologically confirmed

• Participants who have received no more than 2 lines of prior systemic therapies which must include anti-programmed cell death protein ligand-1 (anti-PD-(L)1) treatment and a platinum-based chemotherapy administered in combination with, or sequentially before or after the anti-PD-(L)1 treatment

• At least 1 measurable lesion as defined per RECIST v1.1

• Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1

• Adequate organ function as indicated by laboratory values during screening

Exclusion Criteria:

• With mixed small cell lung cancer

• Has received prior therapy targeting OX40 or any other T-cell agonists

• Has received prior therapy containing docetaxel and/or ramucirumab for advanced or metastatic NSCLC

• Has received any Chinese herbal medicine or Chinese patent medicines used to control cancer ≤ 14 days before the first dose of study drug(s)

• Active leptomeningeal disease or uncontrolled and untreated brain metastasis

NOTE: Other criteria may apply